PE20110945A1 - Nuevo procedimiento de preparacion de granulados de principios activos y granulados tal como se lo ha obtenido - Google Patents

Nuevo procedimiento de preparacion de granulados de principios activos y granulados tal como se lo ha obtenido

Info

Publication number
PE20110945A1
PE20110945A1 PE2011001032A PE2011001032A PE20110945A1 PE 20110945 A1 PE20110945 A1 PE 20110945A1 PE 2011001032 A PE2011001032 A PE 2011001032A PE 2011001032 A PE2011001032 A PE 2011001032A PE 20110945 A1 PE20110945 A1 PE 20110945A1
Authority
PE
Peru
Prior art keywords
active principles
granulates
preparation
alcoholic
new procedure
Prior art date
Application number
PE2011001032A
Other languages
English (en)
Spanish (es)
Inventor
Christophe Lebon
Pascal Suplie
Original Assignee
Debregeas Et Associes Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40348849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110945(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debregeas Et Associes Pharma filed Critical Debregeas Et Associes Pharma
Publication of PE20110945A1 publication Critical patent/PE20110945A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Fertilizers (AREA)
  • Glanulating (AREA)
  • Seasonings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fodder In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2011001032A 2008-11-14 2009-11-13 Nuevo procedimiento de preparacion de granulados de principios activos y granulados tal como se lo ha obtenido PE20110945A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0857764A FR2938432B1 (fr) 2008-11-14 2008-11-14 Nouveau procede de preparation de granules de principes actifs, et granules tels qu'obtenus

Publications (1)

Publication Number Publication Date
PE20110945A1 true PE20110945A1 (es) 2012-02-01

Family

ID=40348849

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001032A PE20110945A1 (es) 2008-11-14 2009-11-13 Nuevo procedimiento de preparacion de granulados de principios activos y granulados tal como se lo ha obtenido

Country Status (25)

Country Link
US (1) US20110280945A1 (cg-RX-API-DMAC7.html)
EP (1) EP2349226A1 (cg-RX-API-DMAC7.html)
JP (1) JP5608681B2 (cg-RX-API-DMAC7.html)
KR (1) KR101585705B1 (cg-RX-API-DMAC7.html)
CN (1) CN102223879A (cg-RX-API-DMAC7.html)
AR (1) AR074330A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009315449B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0916019A2 (cg-RX-API-DMAC7.html)
CA (1) CA2743753A1 (cg-RX-API-DMAC7.html)
CL (1) CL2011001115A1 (cg-RX-API-DMAC7.html)
CO (1) CO6382108A2 (cg-RX-API-DMAC7.html)
CU (1) CU20110107A7 (cg-RX-API-DMAC7.html)
EA (1) EA201100757A1 (cg-RX-API-DMAC7.html)
FR (1) FR2938432B1 (cg-RX-API-DMAC7.html)
IL (1) IL212850A0 (cg-RX-API-DMAC7.html)
MA (1) MA32789B1 (cg-RX-API-DMAC7.html)
MX (1) MX2011005072A (cg-RX-API-DMAC7.html)
NZ (1) NZ592857A (cg-RX-API-DMAC7.html)
PE (1) PE20110945A1 (cg-RX-API-DMAC7.html)
SG (1) SG195651A1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000235A1 (cg-RX-API-DMAC7.html)
TW (1) TWI522113B (cg-RX-API-DMAC7.html)
UA (1) UA103781C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010055268A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201103543B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2971422B1 (fr) * 2011-02-11 2016-05-20 Debregeas Et Associes Pharma Granules d'acide gamma-hydroxybutyrique
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
US9241956B2 (en) * 2012-11-05 2016-01-26 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
US11058635B1 (en) * 2020-10-15 2021-07-13 King Abdulaziz University Oral administration of 5-FU in a gelling nanosuspension for targeted delivery to treat colorectal cancers
KR20240157168A (ko) * 2023-04-24 2024-11-01 주식회사 케이티앤지 바인더를 사용하는 파우치 충진 물질의 제조 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6327424A (ja) * 1986-07-17 1988-02-05 Shionogi & Co Ltd 徐放性製剤およびその製造法
JP2820829B2 (ja) * 1991-03-07 1998-11-05 武田薬品工業株式会社 有核散剤およびその製造方法
JPH08310969A (ja) * 1995-05-22 1996-11-26 Lion Corp 固形薬品組成物及びその製造方法
FR2790668B1 (fr) * 1999-03-12 2002-07-26 D B F Granules contenant une substance vegetale et leur procede de preparation
JP2002544220A (ja) * 1999-05-17 2002-12-24 デー.ベー.エフ. 植物物質を含有する顆粒及びその製造方法
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US9247765B2 (en) * 2004-01-14 2016-02-02 Omniactive Health Technologies Limited Stable beadlets of lipophilic nutrients
FR2880541B1 (fr) * 2005-01-10 2008-02-22 Amalric Veret Une nouvelle formule de plantes sous forme de micro-granules de xilitol pour renforcer les effets des plantes et leurs proprietes par une meilleure assimilation
US20060182796A1 (en) * 2005-02-03 2006-08-17 Abrika Pharmaceuticals, Inc. Taste masked pharmaceutical compositions
NZ575171A (en) * 2006-08-31 2012-04-27 Aptalis Pharmatech Inc Drug delivery systems comprising solid solutions of weakly basic drugs
ES2403103T3 (es) * 2007-02-14 2013-05-14 Dainichiseika Color & Chemicals Mfg. Co., Ltd. Agente dispersante para pigmento orgánico y su utilización
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system

Also Published As

Publication number Publication date
ZA201103543B (en) 2012-01-25
US20110280945A1 (en) 2011-11-17
EA201100757A1 (ru) 2011-12-30
FR2938432A1 (fr) 2010-05-21
CU20110107A7 (es) 2012-01-31
CN102223879A (zh) 2011-10-19
CO6382108A2 (es) 2012-02-15
JP2012508786A (ja) 2012-04-12
EP2349226A1 (fr) 2011-08-03
AU2009315449B2 (en) 2015-03-26
NZ592857A (en) 2013-07-26
MA32789B1 (fr) 2011-11-01
UA103781C2 (uk) 2013-11-25
TWI522113B (zh) 2016-02-21
SG195651A1 (en) 2013-12-30
KR20110095888A (ko) 2011-08-25
AR074330A1 (es) 2011-01-05
CA2743753A1 (fr) 2010-05-20
AU2009315449A1 (en) 2010-05-20
CL2011001115A1 (es) 2011-11-11
WO2010055268A1 (fr) 2010-05-20
IL212850A0 (en) 2011-07-31
JP5608681B2 (ja) 2014-10-15
BRPI0916019A2 (pt) 2015-11-10
KR101585705B1 (ko) 2016-01-15
TW201029667A (en) 2010-08-16
FR2938432B1 (fr) 2011-05-20
MX2011005072A (es) 2011-10-03
TN2011000235A1 (fr) 2012-12-17

Similar Documents

Publication Publication Date Title
CL2013002505A1 (es) Composicion farmaceutica oral solida que comprende a) un nucleo de liberacion prolongada que contiene metformina, b) un recubrimiento sellador opcional, y c) un recubrimiento externo de liberacion inmediata que comprende a un agente activo, tal como un inhibidor de dpp-4 o de sglt-2; uso para tratar diabetes mellitus tipo 2.
AR053292A1 (es) Un sistema de suministro para dos o mas componentes acivos como parte de una composicion comestible
WO2009100441A3 (en) Depot formulations
BRPI0609424B8 (pt) composto inibidor da dipeptidil peptidase-iv e composição farmacêutica compreendendo dito composto como um agente ativo
AR077864A1 (es) Microgranulos flotantes
EP1932530A4 (en) MEANS FOR IMPROVING COLLAGEN PRODUCTION AND ITS USE
PE20061091A1 (es) FORMA CRISTALINA BETA-d DEL CLORHIDRATO DE IVABRANDINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
CL2008002206A1 (es) Composicion veterinaria topica que comprende praziquantel, un segundo agente endoparasiticida seleccionado entre una lactona macrociclica, imidacloprid y una combinacion de estos, y 4-alil-2-metoxifenol como portador; proceso de preparacion; y su uso
UY31079A1 (es) Derivados de fenilaminobenceno sustituidos de utilidad para el tratamiento de trastornos y enfermedades hiperproliferativos asociados con actividad quinasa extracelular mediada por mitógenos
CL2011001586A1 (es) Metodo que comprende una composicion que contiene sulfoximida de 6-haloalquilpiridin-3-il-alquilo n-sustituida; composicion comprendiendo una mezcla estereoisomera de dicha sulfoximida en una formulacion farmaceutica acuosa.
CO6390034A2 (es) Uso de una composición espumable esencialmente libre de ingredientes con actividad farmacéutica para el tratamiento de la piel humana
CL2007003820A1 (es) Compuestos derivados de isoquinolinona sustituidos con cicloalquilamina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar y/o prevenir hipertension, retinopatia, glaucoma, fibrosis pulmonar, alzheimer, sida, entre otra
BRPI1015447A8 (pt) Soluções pediátricas compreendendo um bloqueador beta
CL2007002682A1 (es) Compuestos derivados de 4-metilpiridopirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar el crecimiento anormal de celulas, como cancer.
PE20141585A1 (es) Composicion farmaceutica estabilizada a base de un compuesto no petidico
CL2009000707A1 (es) Composicion controladora de enfermedades de plantas que comprende un compuesto derivado de pirazolinona y al menos otros fungicidas derivados de estrobirulina como dimoxiestrobina; y metodo para controlar una enfermedad en planta mediante el uso de la composicion.
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
CR20120357A (es) Composición que comprende un pesticida y un alcoxilato de 2-propilheptilamina
EP2153831A4 (en) ANTIERMÜDUNGSMITTEL AND ORAL COMPOSITION, BOTH WITH ANDROGRAPHOLIDE AS ACTIVE INGREDIENTS
CL2008001048A1 (es) Compuestos derivados de heterociclos nitrogenados; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como antibacterianos.
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
CL2007002862A1 (es) Uso del factor de crecimiento epidermico (egf) para tratar neuropatia sensitivo-motora, dolorosa y manifestaciones de neuritis isquemicas; composicion farmaceutica que comprende egf; y uso de la composicion antes dicha.
WO2009138847A3 (en) An improved process for the preparation of cefozopran

Legal Events

Date Code Title Description
FD Application declared void or lapsed